{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T22:30:40Z","timestamp":1782340240474,"version":"3.54.5"},"reference-count":54,"publisher":"Innovative Healthcare Institute","issue":"4","license":[{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,25]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>This study aims to document patient characteristics, treatment modalities, and survival outcomes of patients with lung cancer in Vietnam from 2018 to 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a retrospective study of patients with lung cancer treated at Nghe An Oncology Hospital over a 6-year period (2018\u20132024). The primary endpoints included lung cancer treatment methods for non\u2013small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) and overall survival (OS). Secondary endpoints involved factors related to survival duration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 3548 patients were included: 3087 with NSCLC (87%) and 419 with SCLC (11.8%) (median age 64 years, range 18\u201397 years; 3:1 male-to-female ratio). Adenocarcinoma (AC) was the predominant histologic subtype (67%), followed by squamous cell carcinoma (SCC) (13.4%).\n                      <jats:italic>EGFR<\/jats:italic>\n                      mutation was detected in 43.2% of cases. From 2018 to 2024, the proportion of early-stage lung cancer diagnoses (stages I and II) increased from 2.7% to 9%, and the detection rate of advanced or metastatic stages (stages III and IV) decreased. Surgery was the primary treatment for localized NSCLC (62.5%), and stage III cases predominantly received radiation and chemotherapy (40.8%), including 38.6% with concurrent chemoradiotherapy. In stage IV NSCLC, chemotherapy was the most common treatment (53.9%), followed by targeted therapy (25.2%) and immunotherapy (1.9%). SCLC was mostly diagnosed at the extensive stage (68.0%), with chemotherapy being the mainstay of treatment (73.0%), followed by chemoradiotherapy (12.9%) and palliative care (13.1%). Median OS was 15.3 months (95% CI, 14.5\u201316.1), with a 5-year survival rate of 14.2%. Median OS for NSCLC cases was 16.4 months (95% CI, 15.4\u201317.4), with 5-year survival rates of 55.2%, 47.6%, 20.2%, and 8.3% for stages I, II, III, and IV, respectively. Median OS for SCLC cases was 11.0 months (95% CI, 9.7\u201312.4), with a 5-year survival rate of 4.7%. Independent prognostic factors for mortality included male sex, poor performance status (PS \u2265 2), small cell histology, metastatic disease, brain metastases, and initial nonsurgical treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study provides critical data on the epidemiology and prognosis of lung cancer in Vietnam, highlighting the role of personalized treatment approaches in improving clinical outcomes. These findings underscore the urgent need for integrated public health strategies to enhance early detection and access to advanced therapies, thereby reducing the lung cancer burden in Vietnam.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.36401\/jipo-25-12","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T20:01:03Z","timestamp":1764100863000},"page":"254-262","source":"Crossref","is-referenced-by-count":4,"title":["Lung Cancer Outcomes in Vietnam: A 6-Year Retrospective Study"],"prefix":"10.36401","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-5862-3874","authenticated-orcid":true,"given":"Khanh Toan","family":"Nguyen","sequence":"first","affiliation":[{"name":"Nghe An Oncology Hospital, Vinh, Nghe An Province, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thi Huong","family":"Pham","sequence":"additional","affiliation":[{"name":"Nghe An Oncology Hospital, Vinh, Nghe An Province, Vietnam"},{"name":"Hanoi Medical University, Hanoi, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Van Lam","family":"Ngo","sequence":"additional","affiliation":[{"name":"Nghe An Oncology Hospital, Vinh, Nghe An Province, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thi Thuy My","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Nghe An Oncology Hospital, Vinh, Nghe An Province, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thi Dao","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Nghe An Oncology Hospital, Vinh, Nghe An Province, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Van Thanh","family":"Le","sequence":"additional","affiliation":[{"name":"Nghe An Oncology Hospital, Vinh, Nghe An Province, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Van Nhat","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Nghe An Oncology Hospital, Vinh, Nghe An Province, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thi Thanh Thuy","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Nghe An Oncology Hospital, Vinh, Nghe An Province, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khanh Ha","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Nghe An Oncology Hospital, Vinh, Nghe An Province, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thi Nhung","family":"Ngo","sequence":"additional","affiliation":[{"name":"Nghe An Oncology Hospital, Vinh, Nghe An Province, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thi Hai Yen","family":"Le","sequence":"additional","affiliation":[{"name":"Nghe An Oncology Hospital, Vinh, Nghe An Province, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thi Phuong Thao","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Nghe An Oncology Hospital, Vinh, Nghe An Province, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thi Ha Phuong","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Nghe An Oncology Hospital, Vinh, Nghe An Province, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thi Hong Anh","family":"Vo","sequence":"additional","affiliation":[{"name":"Nghe An Oncology Hospital, Vinh, Nghe An Province, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thi Thuy","family":"Phan","sequence":"additional","affiliation":[{"name":"Nghe An Oncology Hospital, Vinh, Nghe An Province, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khanh Hung","family":"Truong","sequence":"additional","affiliation":[{"name":"Nghe An Oncology Hospital, Vinh, Nghe An Province, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ba Duc","family":"Ho","sequence":"additional","affiliation":[{"name":"Nghe An Oncology Hospital, Vinh, Nghe An Province, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thi My Linh","family":"Dinh","sequence":"additional","affiliation":[{"name":"Nghe An Oncology Hospital, Vinh, Nghe An Province, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22027","reference":[{"key":"i2590-017X-8-4-254-b01","series-title":"CA Cancer J Clin","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","unstructured":"Bray F,\nLaversanne M,\nSung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u2013263."},{"key":"i2590-017X-8-4-254-b02","series-title":"Cancer Control","first-page":"1073274819865274","article-title":"Projecting cancer incidence for 2025 in the 2 largest populated cities in Vietnam","volume":"26","author":"Nguyen","year":"2019","unstructured":"Nguyen SM,\nDeppen S,\nNguyen GH, et al. Projecting cancer incidence for 2025 in the 2 largest populated cities in Vietnam. Cancer Control. 2019;26:1073274819865274."},{"key":"i2590-017X-8-4-254-b03","series-title":"Lancet Reg Health Southeast Asia","first-page":"100333","article-title":"Temporal patterns of cancer burden in Asia, 1990-2019: a systematic examination for the Global Burden of Disease 2019 study","volume":"21","author":"GBD 2019 Asia and All Cancers Collaborators","year":"2024","unstructured":"GBD 2019 Asia and All Cancers Collaborators. Temporal patterns of cancer burden in Asia, 1990-2019: a systematic examination for the Global Burden of Disease 2019 study. Lancet Reg Health Southeast Asia. 2024;21:100333."},{"key":"i2590-017X-8-4-254-b04","series-title":"Lancet","first-page":"1204","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"396","author":"GBD 2019 Diseases and Injuries Collaborators","year":"2020","unstructured":"GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396:1204\u20131222."},{"key":"i2590-017X-8-4-254-b05","series-title":"Cancer Manag Res","first-page":"943","article-title":"Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades","volume":"11","author":"Lu","year":"2019","unstructured":"Lu T,\nYang X,\nHuang Y, et al. Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades. Cancer Manag Res. 2019;11:943\u2013953."},{"key":"i2590-017X-8-4-254-b06","series-title":"Contemp Oncol (Pozn)","first-page":"45","article-title":"Epidemiology of lung cancer","volume":"25","author":"Thandra","year":"2021","unstructured":"Thandra KC,\nBarsouk A,\nSaginala K, et al. Epidemiology of lung cancer. Contemp Oncol (Pozn). 2021;25:45\u201352."},{"key":"i2590-017X-8-4-254-b07","series-title":"Cancers (Basel)","first-page":"3711","article-title":"The role of surgery in lung cancer treatment: present indications and future perspectives-state of the art","volume":"13","author":"Montagne","year":"2021","unstructured":"Montagne F,\nGuisier F,\nVenissac N,\nBaste JM. The role of surgery in lung cancer treatment: present indications and future perspectives-state of the art. Cancers (Basel). 2021;13:3711."},{"key":"i2590-017X-8-4-254-b08","series-title":"BMC Cancer","first-page":"603","article-title":"Treatment patterns and outcomes of patients with metastatic non-small cell lung cancer in five European countries: a real-world evidence survey","volume":"23","author":"Bailey","year":"2023","unstructured":"Bailey H,\nLee A,\nEccles L, et al. Treatment patterns and outcomes of patients with metastatic non-small cell lung cancer in five European countries: a real-world evidence survey. BMC Cancer. 2023;23:603."},{"key":"i2590-017X-8-4-254-b09","series-title":"Mayo Clinic Proc","first-page":"1599","article-title":"Current diagnosis and management of small-cell lung cancer","volume":"94","author":"Wang","year":"2019","unstructured":"Wang S,\nZimmermann S,\nParikh K, et al. Current diagnosis and management of small-cell lung cancer. Mayo Clinic Proc. 2019;94:1599\u20131622."},{"key":"i2590-017X-8-4-254-b10","series-title":"Lung","first-page":"897","article-title":"Update 2020: management of non-small cell lung cancer","volume":"198","author":"Alexander","year":"2020","unstructured":"Alexander M,\nKim SY,\nCheng H. Update 2020: management of non-small cell lung cancer. Lung. 2020;198:897\u2013907."},{"key":"i2590-017X-8-4-254-b11","series-title":"Heliyon","first-page":"e40147","article-title":"Treatment patterns and outcomes in patients with non-small cell lung cancer","volume":"10","author":"Richy","year":"2024","unstructured":"Richy FF,\nKumar D,\nFreres P. Treatment patterns and outcomes in patients with non-small cell lung cancer. Heliyon. 2024;10:e40147."},{"key":"i2590-017X-8-4-254-b12","series-title":"Cancer Res Treat","first-page":"103","article-title":"Five-year overall survival and prognostic factors in patients with lung cancer: results from the Korean Association of Lung Cancer Registry (KALC-R) 2015","volume":"55","author":"Jeon","year":"2023","unstructured":"Jeon DS,\nKim HC,\nKim SH, et al. Five-year overall survival and prognostic factors in patients with lung cancer: results from the Korean Association of Lung Cancer Registry (KALC-R) 2015. Cancer Res Treat. 2023;55:103\u2013111."},{"key":"i2590-017X-8-4-254-b13","series-title":"Transl Lung Cancer Res","first-page":"1591","article-title":"Survival of 7,311 lung cancer patients by pathological stage and histological classification: a multicenter hospital-based study in China","volume":"11","author":"He","year":"2022","unstructured":"He S,\nLi H,\nCao M, et al. Survival of 7,311 lung cancer patients by pathological stage and histological classification: a multicenter hospital-based study in China. Transl Lung Cancer Res. 2022;11:1591\u20131605."},{"key":"i2590-017X-8-4-254-b14","series-title":"BMC Pulm Med","first-page":"322","article-title":"Epidemiological and therapeutic profiles of lung cancer patients in the Hokushin Region Japan: a retrospective hospital administrative database study","volume":"23","author":"Kobayashi","year":"2023","unstructured":"Kobayashi T,\nNishino Y,\nTakiguchi T, et al. Epidemiological and therapeutic profiles of lung cancer patients in the Hokushin Region Japan: a retrospective hospital administrative database study. BMC Pulm Med. 2023;23:322."},{"key":"i2590-017X-8-4-254-b15","article-title":"Lung and Bronchus Cancer: Cancer Stat Facts","unstructured":"Lung and Bronchus Cancer: Cancer Stat Facts. National Cancer Institute, SEER. Accessed April 2025. seer.cancer.gov\/statfacts\/html\/lungb.html"},{"key":"i2590-017X-8-4-254-b16","series-title":"J Thorac Oncol","first-page":"1355","article-title":"Stage migration and lung cancer incidence after initiation of low-dose computed tomography screening","volume":"17","author":"Vachani","year":"2022","unstructured":"Vachani A,\nCarroll NM,\nSimoff MJ, et al. Stage migration and lung cancer incidence after initiation of low-dose computed tomography screening. J Thorac Oncol. 2022;17:1355\u20131364."},{"key":"i2590-017X-8-4-254-b17","series-title":"J Thorac Oncol","first-page":"154","article-title":"A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)","volume":"9","author":"Shi","year":"2014","unstructured":"Shi Y,\nAu JS,\nThongprasert S, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol. 2014;9:154\u2013162."},{"key":"i2590-017X-8-4-254-b18","series-title":"World J Clin Oncol","first-page":"217","article-title":"Oncogenic driver mutations in non-small cell lung cancer: past, present and future","volume":"12","author":"Chevallier","year":"2021","unstructured":"Chevallier M,\nBorgeaud M,\nAddeo A,\nFriedlaender A. Oncogenic driver mutations in non-small cell lung cancer: past, present and future. World J Clin Oncol. 2021;12:217\u2013237."},{"key":"i2590-017X-8-4-254-b19","series-title":"Adv Cancer Biol Metastasis","first-page":"100076","article-title":"Non-small-cell lung cancer-associated gene mutations and inhibitors","volume":"6","author":"Kumar","year":"2022","unstructured":"Kumar A,\nKumar A. Non-small-cell lung cancer-associated gene mutations and inhibitors. Adv Cancer Biol Metastasis. 2022;6:100076."},{"key":"i2590-017X-8-4-254-b20","series-title":"Lung","first-page":"579","article-title":"Update 2021: management of small cell lung cancer","volume":"199","author":"Tariq","year":"2021","unstructured":"Tariq S,\nKim SY,\nMonteiro de Oliveira Novaes J,\nCheng H. Update 2021: management of small cell lung cancer. Lung. 2021;199:579\u2013587."},{"key":"i2590-017X-8-4-254-b21","series-title":"JAMA Oncol","first-page":"1824","article-title":"Update of incidence, prevalence, survival, and initial treatment in patients with non\u2013small cell lung cancer in the US","volume":"7","author":"Ganti","year":"2021","unstructured":"Ganti AK,\nKlein AB,\nCotarla I, et al. Update of incidence, prevalence, survival, and initial treatment in patients with non\u2013small cell lung cancer in the US. JAMA Oncol. 2021;7:1824\u20131832."},{"key":"i2590-017X-8-4-254-b22","series-title":"J Clin Oncol","first-page":"2339","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score \u2265 50","volume":"39","author":"Reck","year":"2021","unstructured":"Reck M,\nRodr\u00edguez-Abreu D,\nRobinson AG, et al. Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score \u2265 50. J Clin Oncol. 2021;39:2339\u20132349."},{"key":"i2590-017X-8-4-254-b23","series-title":"J Clin Oncol","first-page":"1992","article-title":"Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study","volume":"41","author":"Garassino","year":"2023","unstructured":"Garassino MC,\nGadgeel S,\nSperanza G, et al. Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study. J Clin Oncol. 2023;41:1992\u20131998."},{"key":"i2590-017X-8-4-254-b24","series-title":"Curr Oncol","first-page":"4093","article-title":"Immunotherapy in extensive-stage small cell lung cancer","volume":"28","author":"El Sayed","year":"2021","unstructured":"El Sayed R,\nBlais N. Immunotherapy in extensive-stage small cell lung cancer. Curr Oncol. 2021;28:4093\u20134108."},{"key":"i2590-017X-8-4-254-b25","series-title":"J Thorac Oncol","first-page":"620","article-title":"Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: a comprehensive analysis of 26,957 patients with NSCLC","volume":"5","author":"Kawaguchi","year":"2010","unstructured":"Kawaguchi T,\nTakada M,\nKubo A, et al. Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: a comprehensive analysis of 26,957 patients with NSCLC. J Thorac Oncol. 2010;5:620\u2013630."},{"key":"i2590-017X-8-4-254-b26","series-title":"Cancer","first-page":"382","article-title":"A pooled analysis of individual patient data from National Clinical Trials Network clinical trials of concurrent chemoradiotherapy for limited-stage small cell lung cancer in elderly patients versus younger patients","volume":"125","author":"Stinchcombe","year":"2019","unstructured":"Stinchcombe TE,\nFan W,\nSchild SE, et al. A pooled analysis of individual patient data from National Clinical Trials Network clinical trials of concurrent chemoradiotherapy for limited-stage small cell lung cancer in elderly patients versus younger patients. Cancer. 2019;125:382\u2013390."},{"issue":"s1","key":"i2590-017X-8-4-254-b27","series-title":"Tumour Biol","first-page":"S283","article-title":"Circulating tumor DNA (ctDNA) as a biomarker for lung cancer: early detection, monitoring and therapy prediction","volume":"46","author":"Duffy","year":"2024","unstructured":"Duffy MJ. Circulating tumor DNA (ctDNA) as a biomarker for lung cancer: early detection, monitoring and therapy prediction. Tumour Biol. 2024;46(s1):S283\u2013S295."},{"key":"i2590-017X-8-4-254-b01","series-title":"CA Cancer J Clin","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","unstructured":"Bray F,\nLaversanne M,\nSung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u2013263."},{"key":"i2590-017X-8-4-254-b02","series-title":"Cancer Control","first-page":"1073274819865274","article-title":"Projecting cancer incidence for 2025 in the 2 largest populated cities in Vietnam","volume":"26","author":"Nguyen","year":"2019","unstructured":"Nguyen SM,\nDeppen S,\nNguyen GH, et al. Projecting cancer incidence for 2025 in the 2 largest populated cities in Vietnam. Cancer Control. 2019;26:1073274819865274."},{"key":"i2590-017X-8-4-254-b03","series-title":"Lancet Reg Health Southeast Asia","first-page":"100333","article-title":"Temporal patterns of cancer burden in Asia, 1990-2019: a systematic examination for the Global Burden of Disease 2019 study","volume":"21","author":"GBD 2019 Asia and All Cancers Collaborators","year":"2024","unstructured":"GBD 2019 Asia and All Cancers Collaborators. Temporal patterns of cancer burden in Asia, 1990-2019: a systematic examination for the Global Burden of Disease 2019 study. Lancet Reg Health Southeast Asia. 2024;21:100333."},{"key":"i2590-017X-8-4-254-b04","series-title":"Lancet","first-page":"1204","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"396","author":"GBD 2019 Diseases and Injuries Collaborators","year":"2020","unstructured":"GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396:1204\u20131222."},{"key":"i2590-017X-8-4-254-b05","series-title":"Cancer Manag Res","first-page":"943","article-title":"Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades","volume":"11","author":"Lu","year":"2019","unstructured":"Lu T,\nYang X,\nHuang Y, et al. Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades. Cancer Manag Res. 2019;11:943\u2013953."},{"key":"i2590-017X-8-4-254-b06","series-title":"Contemp Oncol (Pozn)","first-page":"45","article-title":"Epidemiology of lung cancer","volume":"25","author":"Thandra","year":"2021","unstructured":"Thandra KC,\nBarsouk A,\nSaginala K, et al. Epidemiology of lung cancer. Contemp Oncol (Pozn). 2021;25:45\u201352."},{"key":"i2590-017X-8-4-254-b07","series-title":"Cancers (Basel)","first-page":"3711","article-title":"The role of surgery in lung cancer treatment: present indications and future perspectives-state of the art","volume":"13","author":"Montagne","year":"2021","unstructured":"Montagne F,\nGuisier F,\nVenissac N,\nBaste JM. The role of surgery in lung cancer treatment: present indications and future perspectives-state of the art. Cancers (Basel). 2021;13:3711."},{"key":"i2590-017X-8-4-254-b08","series-title":"BMC Cancer","first-page":"603","article-title":"Treatment patterns and outcomes of patients with metastatic non-small cell lung cancer in five European countries: a real-world evidence survey","volume":"23","author":"Bailey","year":"2023","unstructured":"Bailey H,\nLee A,\nEccles L, et al. Treatment patterns and outcomes of patients with metastatic non-small cell lung cancer in five European countries: a real-world evidence survey. BMC Cancer. 2023;23:603."},{"key":"i2590-017X-8-4-254-b09","series-title":"Mayo Clinic Proc","first-page":"1599","article-title":"Current diagnosis and management of small-cell lung cancer","volume":"94","author":"Wang","year":"2019","unstructured":"Wang S,\nZimmermann S,\nParikh K, et al. Current diagnosis and management of small-cell lung cancer. Mayo Clinic Proc. 2019;94:1599\u20131622."},{"key":"i2590-017X-8-4-254-b10","series-title":"Lung","first-page":"897","article-title":"Update 2020: management of non-small cell lung cancer","volume":"198","author":"Alexander","year":"2020","unstructured":"Alexander M,\nKim SY,\nCheng H. Update 2020: management of non-small cell lung cancer. Lung. 2020;198:897\u2013907."},{"key":"i2590-017X-8-4-254-b11","series-title":"Heliyon","first-page":"e40147","article-title":"Treatment patterns and outcomes in patients with non-small cell lung cancer","volume":"10","author":"Richy","year":"2024","unstructured":"Richy FF,\nKumar D,\nFreres P. Treatment patterns and outcomes in patients with non-small cell lung cancer. Heliyon. 2024;10:e40147."},{"key":"i2590-017X-8-4-254-b12","series-title":"Cancer Res Treat","first-page":"103","article-title":"Five-year overall survival and prognostic factors in patients with lung cancer: results from the Korean Association of Lung Cancer Registry (KALC-R) 2015","volume":"55","author":"Jeon","year":"2023","unstructured":"Jeon DS,\nKim HC,\nKim SH, et al. Five-year overall survival and prognostic factors in patients with lung cancer: results from the Korean Association of Lung Cancer Registry (KALC-R) 2015. Cancer Res Treat. 2023;55:103\u2013111."},{"key":"i2590-017X-8-4-254-b13","series-title":"Transl Lung Cancer Res","first-page":"1591","article-title":"Survival of 7,311 lung cancer patients by pathological stage and histological classification: a multicenter hospital-based study in China","volume":"11","author":"He","year":"2022","unstructured":"He S,\nLi H,\nCao M, et al. Survival of 7,311 lung cancer patients by pathological stage and histological classification: a multicenter hospital-based study in China. Transl Lung Cancer Res. 2022;11:1591\u20131605."},{"key":"i2590-017X-8-4-254-b14","series-title":"BMC Pulm Med","first-page":"322","article-title":"Epidemiological and therapeutic profiles of lung cancer patients in the Hokushin Region Japan: a retrospective hospital administrative database study","volume":"23","author":"Kobayashi","year":"2023","unstructured":"Kobayashi T,\nNishino Y,\nTakiguchi T, et al. Epidemiological and therapeutic profiles of lung cancer patients in the Hokushin Region Japan: a retrospective hospital administrative database study. BMC Pulm Med. 2023;23:322."},{"key":"i2590-017X-8-4-254-b15","article-title":"Lung and Bronchus Cancer: Cancer Stat Facts","unstructured":"Lung and Bronchus Cancer: Cancer Stat Facts. National Cancer Institute, SEER. Accessed April 2025. seer.cancer.gov\/statfacts\/html\/lungb.html"},{"key":"i2590-017X-8-4-254-b16","series-title":"J Thorac Oncol","first-page":"1355","article-title":"Stage migration and lung cancer incidence after initiation of low-dose computed tomography screening","volume":"17","author":"Vachani","year":"2022","unstructured":"Vachani A,\nCarroll NM,\nSimoff MJ, et al. Stage migration and lung cancer incidence after initiation of low-dose computed tomography screening. J Thorac Oncol. 2022;17:1355\u20131364."},{"key":"i2590-017X-8-4-254-b17","series-title":"J Thorac Oncol","first-page":"154","article-title":"A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)","volume":"9","author":"Shi","year":"2014","unstructured":"Shi Y,\nAu JS,\nThongprasert S, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol. 2014;9:154\u2013162."},{"key":"i2590-017X-8-4-254-b18","series-title":"World J Clin Oncol","first-page":"217","article-title":"Oncogenic driver mutations in non-small cell lung cancer: past, present and future","volume":"12","author":"Chevallier","year":"2021","unstructured":"Chevallier M,\nBorgeaud M,\nAddeo A,\nFriedlaender A. Oncogenic driver mutations in non-small cell lung cancer: past, present and future. World J Clin Oncol. 2021;12:217\u2013237."},{"key":"i2590-017X-8-4-254-b19","series-title":"Adv Cancer Biol Metastasis","first-page":"100076","article-title":"Non-small-cell lung cancer-associated gene mutations and inhibitors","volume":"6","author":"Kumar","year":"2022","unstructured":"Kumar A,\nKumar A. Non-small-cell lung cancer-associated gene mutations and inhibitors. Adv Cancer Biol Metastasis. 2022;6:100076."},{"key":"i2590-017X-8-4-254-b20","series-title":"Lung","first-page":"579","article-title":"Update 2021: management of small cell lung cancer","volume":"199","author":"Tariq","year":"2021","unstructured":"Tariq S,\nKim SY,\nMonteiro de Oliveira Novaes J,\nCheng H. Update 2021: management of small cell lung cancer. Lung. 2021;199:579\u2013587."},{"key":"i2590-017X-8-4-254-b21","series-title":"JAMA Oncol","first-page":"1824","article-title":"Update of incidence, prevalence, survival, and initial treatment in patients with non\u2013small cell lung cancer in the US","volume":"7","author":"Ganti","year":"2021","unstructured":"Ganti AK,\nKlein AB,\nCotarla I, et al. Update of incidence, prevalence, survival, and initial treatment in patients with non\u2013small cell lung cancer in the US. JAMA Oncol. 2021;7:1824\u20131832."},{"key":"i2590-017X-8-4-254-b22","series-title":"J Clin Oncol","first-page":"2339","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score \u2265 50","volume":"39","author":"Reck","year":"2021","unstructured":"Reck M,\nRodr\u00edguez-Abreu D,\nRobinson AG, et al. Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score \u2265 50. J Clin Oncol. 2021;39:2339\u20132349."},{"key":"i2590-017X-8-4-254-b23","series-title":"J Clin Oncol","first-page":"1992","article-title":"Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study","volume":"41","author":"Garassino","year":"2023","unstructured":"Garassino MC,\nGadgeel S,\nSperanza G, et al. Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study. J Clin Oncol. 2023;41:1992\u20131998."},{"key":"i2590-017X-8-4-254-b24","series-title":"Curr Oncol","first-page":"4093","article-title":"Immunotherapy in extensive-stage small cell lung cancer","volume":"28","author":"El Sayed","year":"2021","unstructured":"El Sayed R,\nBlais N. Immunotherapy in extensive-stage small cell lung cancer. Curr Oncol. 2021;28:4093\u20134108."},{"key":"i2590-017X-8-4-254-b25","series-title":"J Thorac Oncol","first-page":"620","article-title":"Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: a comprehensive analysis of 26,957 patients with NSCLC","volume":"5","author":"Kawaguchi","year":"2010","unstructured":"Kawaguchi T,\nTakada M,\nKubo A, et al. Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: a comprehensive analysis of 26,957 patients with NSCLC. J Thorac Oncol. 2010;5:620\u2013630."},{"key":"i2590-017X-8-4-254-b26","series-title":"Cancer","first-page":"382","article-title":"A pooled analysis of individual patient data from National Clinical Trials Network clinical trials of concurrent chemoradiotherapy for limited-stage small cell lung cancer in elderly patients versus younger patients","volume":"125","author":"Stinchcombe","year":"2019","unstructured":"Stinchcombe TE,\nFan W,\nSchild SE, et al. A pooled analysis of individual patient data from National Clinical Trials Network clinical trials of concurrent chemoradiotherapy for limited-stage small cell lung cancer in elderly patients versus younger patients. Cancer. 2019;125:382\u2013390."},{"issue":"s1","key":"i2590-017X-8-4-254-b27","series-title":"Tumour Biol","first-page":"S283","article-title":"Circulating tumor DNA (ctDNA) as a biomarker for lung cancer: early detection, monitoring and therapy prediction","volume":"46","author":"Duffy","year":"2024","unstructured":"Duffy MJ. Circulating tumor DNA (ctDNA) as a biomarker for lung cancer: early detection, monitoring and therapy prediction. Tumour Biol. 2024;46(s1):S283\u2013S295."}],"container-title":["Journal of Immunotherapy and Precision Oncology"],"original-title":[],"link":[{"URL":"https:\/\/innovationsjournals-jipo.kglmeridian.com\/view\/journals\/jipo\/8\/4\/article-p254.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/meridian.allenpress.com\/innovationsjournals-JIPO\/article-pdf\/8\/4\/254\/3546590\/10.36401_jipo-25-12.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/innovationsjournals-jipo.kglmeridian.com\/downloadpdf\/journals\/jipo\/8\/4\/article-p254.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/innovationsjournals-jipo.kglmeridian.com\/downloadpdf\/journals\/jipo\/8\/4\/article-p254.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T00:44:29Z","timestamp":1771634669000},"score":1,"resource":{"primary":{"URL":"https:\/\/innovationsjournals-jipo.kglmeridian.com\/view\/journals\/jipo\/8\/4\/article-p254.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":54,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.36401\/jipo-25-12","relation":{},"ISSN":["2590-017X","2666-2345"],"issn-type":[{"value":"2590-017X","type":"electronic"},{"value":"2666-2345","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,25]]}}}